Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
Identifieur interne : 000467 ( Main/Exploration ); précédent : 000466; suivant : 000468Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
Auteurs : Javier Ruiz-Martínez [Espagne] ; Patricia De La Riva ; Maria C. Rodríguez-Oroz ; Elisabet Mondrag N Rezola ; Alberto Bergareche ; Ana Gorostidi ; Belen Gago ; Ainara Estanga ; Nerea Larra Aga ; Cristina Sarasqueta ; Adolfo L Pez De Munain ; José F. Martí MassSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Analysis of Variance, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Neoplasms (epidemiology), Parkinson Disease (epidemiology), Parkinson Disease (genetics), Polymorphism, Single Nucleotide (genetics), Prevalence, Protein-Serine-Threonine Kinases (genetics).
- MESH :
- chemical , genetics : Protein-Serine-Threonine Kinases.
- epidemiology : Neoplasms, Parkinson Disease.
- genetics : Parkinson Disease, Polymorphism, Single Nucleotide.
- Adult, Aged, Aged, 80 and over, Analysis of Variance, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Prevalence.
Abstract
An inverse relationship between Parkinson's disease (PD) and cancer has been described. However, the association between cancers and genetic forms of PD, in particular the R1441G mutation in the LRRK2 gene, is not well known. The objective of this work was to analyze cancer prevalence in PD patients with R1441G or G2019S mutations in LRRK2, and in idiopathic PD (iPD). A total of 732 patients with PD (70 and 25 carriers of R1441G or G2019S mutations, respectively), and 177 controls, were linked using a population-based cancer registry of the Spanish province of Gipuzkoa. Cancer prevalence was not significantly higher in PD-G2019S carriers (20%) than in PD-R1441G carriers (14.3%), iPD (13.8%), or controls (12.5%). With the exception of a high prevalence of hematological cancers (crude odds ratio of 7.1) in the R1441G group, specific cancer types were not increased in PD mutation carriers. In both the carrier and iPD groups, cancers were diagnosed after the onset of PD. PD patients had a similar prevalence of cancer to control subjects. There was no increased association between G2019S or R1441G mutations and any type of cancer. Although there was a higher prevalence of hematological cancers in the R1441G group, the low number of such cancers overall makes this finding of uncertain significance. There was a slightly higher but not statistically significant prevalence of non-skin cancers in the G2019S group, suggesting that further study to evaluate the association should be undertaken prior to ascribing an increased cancer risk to this population.
DOI: 10.1002/mds.25778
PubMed: 24357540
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000646
- to stream PubMed, to step Curation: 000646
- to stream PubMed, to step Checkpoint: 000471
- to stream Ncbi, to step Merge: 003E51
- to stream Ncbi, to step Curation: 003E51
- to stream Ncbi, to step Checkpoint: 003E51
- to stream Main, to step Merge: 000467
- to stream Main, to step Curation: 000467
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.</title><author><name sortKey="Ruiz Martinez, Javier" sort="Ruiz Martinez, Javier" uniqKey="Ruiz Martinez J" first="Javier" last="Ruiz-Martínez">Javier Ruiz-Martínez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University Hospital Donostia, San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain; Neurosciences Area, Biodonostia Institute, San Sebastián, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, University Hospital Donostia, San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain; Neurosciences Area, Biodonostia Institute, San Sebastián</wicri:regionArea><wicri:noRegion>San Sebastián</wicri:noRegion></affiliation></author><author><name sortKey="De La Riva, Patricia" sort="De La Riva, Patricia" uniqKey="De La Riva P" first="Patricia" last="De La Riva">Patricia De La Riva</name></author><author><name sortKey="Rodriguez Oroz, Maria C" sort="Rodriguez Oroz, Maria C" uniqKey="Rodriguez Oroz M" first="Maria C" last="Rodríguez-Oroz">Maria C. Rodríguez-Oroz</name></author><author><name sortKey="Mondrag N Rezola, Elisabet" sort="Mondrag N Rezola, Elisabet" uniqKey="Mondrag N Rezola E" first="Elisabet" last="Mondrag N Rezola">Elisabet Mondrag N Rezola</name></author><author><name sortKey="Bergareche, Alberto" sort="Bergareche, Alberto" uniqKey="Bergareche A" first="Alberto" last="Bergareche">Alberto Bergareche</name></author><author><name sortKey="Gorostidi, Ana" sort="Gorostidi, Ana" uniqKey="Gorostidi A" first="Ana" last="Gorostidi">Ana Gorostidi</name></author><author><name sortKey="Gago, Belen" sort="Gago, Belen" uniqKey="Gago B" first="Belen" last="Gago">Belen Gago</name></author><author><name sortKey="Estanga, Ainara" sort="Estanga, Ainara" uniqKey="Estanga A" first="Ainara" last="Estanga">Ainara Estanga</name></author><author><name sortKey="Larra Aga, Nerea" sort="Larra Aga, Nerea" uniqKey="Larra Aga N" first="Nerea" last="Larra Aga">Nerea Larra Aga</name></author><author><name sortKey="Sarasqueta, Cristina" sort="Sarasqueta, Cristina" uniqKey="Sarasqueta C" first="Cristina" last="Sarasqueta">Cristina Sarasqueta</name></author><author><name sortKey="L Pez De Munain, Adolfo" sort="L Pez De Munain, Adolfo" uniqKey="L Pez De Munain A" first="Adolfo" last="L Pez De Munain">Adolfo L Pez De Munain</name></author><author><name sortKey="Marti Mass, Jose F" sort="Marti Mass, Jose F" uniqKey="Marti Mass J" first="José F" last="Martí Mass">José F. Martí Mass</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24357540</idno><idno type="pmid">24357540</idno><idno type="doi">10.1002/mds.25778</idno><idno type="wicri:Area/PubMed/Corpus">000646</idno><idno type="wicri:Area/PubMed/Curation">000646</idno><idno type="wicri:Area/PubMed/Checkpoint">000471</idno><idno type="wicri:Area/Ncbi/Merge">003E51</idno><idno type="wicri:Area/Ncbi/Curation">003E51</idno><idno type="wicri:Area/Ncbi/Checkpoint">003E51</idno><idno type="wicri:Area/Main/Merge">000467</idno><idno type="wicri:Area/Main/Curation">000467</idno><idno type="wicri:Area/Main/Exploration">000467</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.</title><author><name sortKey="Ruiz Martinez, Javier" sort="Ruiz Martinez, Javier" uniqKey="Ruiz Martinez J" first="Javier" last="Ruiz-Martínez">Javier Ruiz-Martínez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University Hospital Donostia, San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain; Neurosciences Area, Biodonostia Institute, San Sebastián, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, University Hospital Donostia, San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain; Neurosciences Area, Biodonostia Institute, San Sebastián</wicri:regionArea><wicri:noRegion>San Sebastián</wicri:noRegion></affiliation></author><author><name sortKey="De La Riva, Patricia" sort="De La Riva, Patricia" uniqKey="De La Riva P" first="Patricia" last="De La Riva">Patricia De La Riva</name></author><author><name sortKey="Rodriguez Oroz, Maria C" sort="Rodriguez Oroz, Maria C" uniqKey="Rodriguez Oroz M" first="Maria C" last="Rodríguez-Oroz">Maria C. Rodríguez-Oroz</name></author><author><name sortKey="Mondrag N Rezola, Elisabet" sort="Mondrag N Rezola, Elisabet" uniqKey="Mondrag N Rezola E" first="Elisabet" last="Mondrag N Rezola">Elisabet Mondrag N Rezola</name></author><author><name sortKey="Bergareche, Alberto" sort="Bergareche, Alberto" uniqKey="Bergareche A" first="Alberto" last="Bergareche">Alberto Bergareche</name></author><author><name sortKey="Gorostidi, Ana" sort="Gorostidi, Ana" uniqKey="Gorostidi A" first="Ana" last="Gorostidi">Ana Gorostidi</name></author><author><name sortKey="Gago, Belen" sort="Gago, Belen" uniqKey="Gago B" first="Belen" last="Gago">Belen Gago</name></author><author><name sortKey="Estanga, Ainara" sort="Estanga, Ainara" uniqKey="Estanga A" first="Ainara" last="Estanga">Ainara Estanga</name></author><author><name sortKey="Larra Aga, Nerea" sort="Larra Aga, Nerea" uniqKey="Larra Aga N" first="Nerea" last="Larra Aga">Nerea Larra Aga</name></author><author><name sortKey="Sarasqueta, Cristina" sort="Sarasqueta, Cristina" uniqKey="Sarasqueta C" first="Cristina" last="Sarasqueta">Cristina Sarasqueta</name></author><author><name sortKey="L Pez De Munain, Adolfo" sort="L Pez De Munain, Adolfo" uniqKey="L Pez De Munain A" first="Adolfo" last="L Pez De Munain">Adolfo L Pez De Munain</name></author><author><name sortKey="Marti Mass, Jose F" sort="Marti Mass, Jose F" uniqKey="Marti Mass J" first="José F" last="Martí Mass">José F. Martí Mass</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>DNA Mutational Analysis</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasms (epidemiology)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson Disease (genetics)</term><term>Polymorphism, Single Nucleotide (genetics)</term><term>Prevalence</term><term>Protein-Serine-Threonine Kinases (genetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Protein-Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Neoplasms</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term><term>Polymorphism, Single Nucleotide</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>DNA Mutational Analysis</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An inverse relationship between Parkinson's disease (PD) and cancer has been described. However, the association between cancers and genetic forms of PD, in particular the R1441G mutation in the LRRK2 gene, is not well known. The objective of this work was to analyze cancer prevalence in PD patients with R1441G or G2019S mutations in LRRK2, and in idiopathic PD (iPD). A total of 732 patients with PD (70 and 25 carriers of R1441G or G2019S mutations, respectively), and 177 controls, were linked using a population-based cancer registry of the Spanish province of Gipuzkoa. Cancer prevalence was not significantly higher in PD-G2019S carriers (20%) than in PD-R1441G carriers (14.3%), iPD (13.8%), or controls (12.5%). With the exception of a high prevalence of hematological cancers (crude odds ratio of 7.1) in the R1441G group, specific cancer types were not increased in PD mutation carriers. In both the carrier and iPD groups, cancers were diagnosed after the onset of PD. PD patients had a similar prevalence of cancer to control subjects. There was no increased association between G2019S or R1441G mutations and any type of cancer. Although there was a higher prevalence of hematological cancers in the R1441G group, the low number of such cancers overall makes this finding of uncertain significance. There was a slightly higher but not statistically significant prevalence of non-skin cancers in the G2019S group, suggesting that further study to evaluate the association should be undertaken prior to ascribing an increased cancer risk to this population.</div></front></TEI><affiliations><list><country><li>Espagne</li></country></list><tree><noCountry><name sortKey="Bergareche, Alberto" sort="Bergareche, Alberto" uniqKey="Bergareche A" first="Alberto" last="Bergareche">Alberto Bergareche</name><name sortKey="De La Riva, Patricia" sort="De La Riva, Patricia" uniqKey="De La Riva P" first="Patricia" last="De La Riva">Patricia De La Riva</name><name sortKey="Estanga, Ainara" sort="Estanga, Ainara" uniqKey="Estanga A" first="Ainara" last="Estanga">Ainara Estanga</name><name sortKey="Gago, Belen" sort="Gago, Belen" uniqKey="Gago B" first="Belen" last="Gago">Belen Gago</name><name sortKey="Gorostidi, Ana" sort="Gorostidi, Ana" uniqKey="Gorostidi A" first="Ana" last="Gorostidi">Ana Gorostidi</name><name sortKey="L Pez De Munain, Adolfo" sort="L Pez De Munain, Adolfo" uniqKey="L Pez De Munain A" first="Adolfo" last="L Pez De Munain">Adolfo L Pez De Munain</name><name sortKey="Larra Aga, Nerea" sort="Larra Aga, Nerea" uniqKey="Larra Aga N" first="Nerea" last="Larra Aga">Nerea Larra Aga</name><name sortKey="Marti Mass, Jose F" sort="Marti Mass, Jose F" uniqKey="Marti Mass J" first="José F" last="Martí Mass">José F. Martí Mass</name><name sortKey="Mondrag N Rezola, Elisabet" sort="Mondrag N Rezola, Elisabet" uniqKey="Mondrag N Rezola E" first="Elisabet" last="Mondrag N Rezola">Elisabet Mondrag N Rezola</name><name sortKey="Rodriguez Oroz, Maria C" sort="Rodriguez Oroz, Maria C" uniqKey="Rodriguez Oroz M" first="Maria C" last="Rodríguez-Oroz">Maria C. Rodríguez-Oroz</name><name sortKey="Sarasqueta, Cristina" sort="Sarasqueta, Cristina" uniqKey="Sarasqueta C" first="Cristina" last="Sarasqueta">Cristina Sarasqueta</name></noCountry><country name="Espagne"><noRegion><name sortKey="Ruiz Martinez, Javier" sort="Ruiz Martinez, Javier" uniqKey="Ruiz Martinez J" first="Javier" last="Ruiz-Martínez">Javier Ruiz-Martínez</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000467 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000467 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24357540
|texte= Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24357540" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |